- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07947147
Thread Embedding Acupuncture Added to Antihistamine Treatment for Chronic Urticaria
Evaluation of the Efficacy and Safety of Thread Embedding Acupuncture Combined With an H1 Antihistamine for the Treatment of Chronic Urticaria
This study will test whether adding thread embedding acupuncture to an antihistamine helps adults with chronic hives whose symptoms remain bothersome despite taking the antihistamine. In thread embedding acupuncture, a clinician uses a needle to place a small dissolvable thread at an acupuncture point. The comparison procedure uses the same acupuncture points and a needle, without placing a thread. Both groups take cetirizine.
The researchers plan to enroll 124 adults at three hospitals in Ho Chi Minh City, Vietnam. Participants will be assigned by chance to one of the two groups. They will receive two procedures, two weeks apart. Participants and the people who assess their symptoms will not know which procedure they received. The main assessment compares changes in hives and itching after four weeks. The study will also assess quality of life, a blood marker called total immunoglobulin E, additional antihistamine use, side effects, and whether symptoms return during follow-up through week 8.
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
This multicenter, randomized, sham-controlled, parallel-group trial compares polydioxanone (PDO) thread embedding acupuncture plus cetirizine with sham thread embedding acupuncture plus cetirizine. Eligible adults will complete a 7-day run-in with oral cetirizine 10 mg daily and a daily hives and itch diary. Participants with a 7-day Urticaria Activity Score (UAS7) of at least 16 and a weekly itch score of at least 8 after run-in are eligible for randomization.
The trial plans to randomize 124 participants in a 1:1 ratio using concealed block randomization through REDCap. Participants and outcome assessors are masked to allocation. The statistician will analyze coded groups. Clinicians performing the procedure know the assignment. Procedures are scheduled at baseline and week 2, with a 4-week treatment period and a further 4 weeks of follow-up. The primary analysis compares change from baseline in UAS7 at week 4. Other assessments include UAS7 at weeks 2 and 8, urticaria-related quality of life, serum total IgE, rescue medication use, adverse events, and symptom recurrence. Analyses are planned on an intention-to-treat basis.
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Sang Thanh Do, MD, MSc
- Telefonszám: +84 948 561 030
- E-mail: dtsang@ump.edu.vn
Tanulmányi helyek
-
-
-
Ho Chi Minh City, Vietnam
- Ho Chi Minh City Traditional Medicine Hospital, Outpatient Department
-
Ho Chi Minh City, Vietnam
- Le Van Thinh Hospital, Department of Dermatology
-
Ho Chi Minh City, Vietnam
- University Medical Center Ho Chi Minh City, Branch 3
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Age 18 years or older and willing to provide written informed consent.
- Chronic urticaria diagnosed according to the EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline. Transient wheals and itching occur at least daily for more than 6 weeks despite prior or current use of an H1 antihistamine, without serious systemic symptoms. Individual wheals resolve within 30 minutes to 24 hours.
- UAS7 of at least 16 and weekly itch score of at least 8 after the 7-day run-in.
- No previous thread embedding acupuncture.
Exclusion Criteria:
- Urticaria with an identified cause, including physical or mechanical urticaria.
- Warning signs of systemic or autoinflammatory disease (e.g., Schnitzler syndrome or cryopyrin-associated periodic syndromes), or urticarial vasculitis.
- Cutaneous mast cell disease or erythema multiforme.
- Current or prior severe associated symptoms such as laryngeal edema, acute angioedema, anaphylaxis, or bradykinin-mediated angioedema including hereditary angioedema.
- Other chronic pruritic skin disease that could interfere with assessment.
- History of allergy to implant materials, especially absorbable suture or catgut, or a predisposition to keloid formation.
- Current or recent immunosuppressive therapy or systemic corticosteroids within 2 to 4 weeks (or 30 days) before participation, as specified in the protocol.
- Biologics such as omalizumab, leukotriene receptor antagonists, or H2 antihistamines within 7 to 14 days before screening or randomization, as specified in the protocol.
- H1 antihistamine use above the recommended dose within 3 days before screening.
- Psychotropic medication within the preceding month.
- Malignancy or severe endocrine disorder.
- Serious cardiovascular or cerebrovascular disease, diabetes mellitus, severe hepatic or renal failure, or a hematopoietic disorder.
- Severe debilitation with reduced immune resistance.
- Other serious systemic autoimmune disease, such as systemic lupus erythematosus.
- Cognitive impairment, psychiatric illness, or a communication barrier that prevents participation in the treatment procedures.
- A nonabsorbable implant at the intended procedure site.
- Pregnancy, breastfeeding, or plans to become pregnant during the study.
- Participation in another clinical trial in the preceding 3 months.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Kettős
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: PDO Thread Embedding Acupuncture Plus Cetirizine
Participants receive polydioxanone (PDO) thread embedding acupuncture at baseline and week 2, plus oral cetirizine as background treatment. |
An absorbable monofilament polydioxanone (PDO) thread is implanted at seven bilateral acupuncture points (14 sites) at baseline and week 2. Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded. |
|
Sham Comparator: Sham Thread Embedding Acupuncture Plus Cetirizine
Participants receive a sham procedure at the same acupuncture points at baseline and week 2. The clinician uses an empty needle, so no thread is implanted. Participants also receive oral cetirizine as background treatment. |
Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded. The clinician inserts and withdraws an empty needle at the same acupuncture points at baseline and week 2. The procedure leaves no implanted thread. |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Change From Baseline in 7-Day Urticaria Activity Score (UAS7) at Week 4
Időkeret: Baseline and week 4
|
UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline. |
Baseline and week 4
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Change From Baseline in UAS7 at Weeks 2 and 8
Időkeret: Baseline and weeks 2 and 8
|
UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline. |
Baseline and weeks 2 and 8
|
|
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score
Időkeret: Baseline and weeks 2, 4, and 8
|
Participants complete the disease-specific questionnaire about how chronic urticaria affected their lives in the preceding two weeks. Higher scores indicate greater impairment. Change is calculated as the follow-up score minus baseline. |
Baseline and weeks 2, 4, and 8
|
|
Change From Baseline in Serum Total Immunoglobulin E (IgE)
Időkeret: Baseline and week 4
|
Serum total IgE is measured by enzyme-linked immunosorbent assay (ELISA) and reported in IU/mL. Change is calculated as the week 4 concentration minus baseline. |
Baseline and week 4
|
|
Proportion of Participants With Adverse Events
Időkeret: From baseline through week 8
|
The study records adverse events and serious adverse events in each group during treatment and follow-up. Event severity is graded using the protocol-specified CTCAE criteria. |
From baseline through week 8
|
|
Proportion of Participants Reporting Recurrence or Flare of Urticaria Symptoms
Időkeret: Weeks 4 through 8
|
Participants are contacted by telephone at week 8 using a standardized script to determine whether symptoms returned or flared during the post-treatment follow-up. |
Weeks 4 through 8
|
|
Number of Rescue Cetirizine Tablets Used
Időkeret: From baseline through week 4
|
The total number of additional cetirizine tablets taken for symptom relief beyond the scheduled background dose is compared between groups. |
From baseline through week 4
|
Egyéb eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Association of Baseline UAS7, Serum Total IgE, and Disease Duration With UAS7 at Week 4
Időkeret: Baseline and week 4
|
A multivariable linear regression will estimate the association of each baseline factor with week 4 UAS7, adjusting for study group and site. |
Baseline and week 4
|
Együttműködők és nyomozók
Nyomozók
- Kutatásvezető: Sang Thanh Do, MD, MSc, University of Medicine and Pharmacy at Ho Chi Minh City
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
- Patológiás folyamatok
- Krónikus betegség
- Betegség tulajdonságai
- Immunrendszeri betegségek
- Túlérzékenység, azonnali
- Túlérzékenység
- Bőrbetegségek
- Urticaria
- Bőrbetegségek, érrendszeri
- Kóros állapotok, jelek és tünetek
- Bőr- és kötőszöveti betegségek
- Krónikus urticaria
- Heterociklusos vegyületek, 1 gyűrű
- Heterociklusos vegyületek
- Piperazinok
- Hidroxizin
- Cetirizin
Egyéb vizsgálati azonosító számok
- 4861/ĐHYD-HĐĐĐ
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .